On Friday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) opened lower -3.50% from the last session, before settling in for the closing price of $11.72. Price fluctuations for IOVA have ranged from $3.21 to $18.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 30.65% at the time writing. With a float of $220.05 million, this company’s outstanding shares have now reached $256.14 million.
The extent of productivity of a business whose workforce counts for 557 workers is very important to gauge.
Iovance Biotherapeutics Inc (IOVA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Iovance Biotherapeutics Inc is 21.21%, while institutional ownership is 67.26%. The most recent insider transaction that took place on Feb 20 ’24, was worth 45,750,000. In this transaction Director of this company bought 5,000,000 shares at a rate of $9.15, taking the stock ownership to the 28,067,333 shares. Before that another transaction happened on Feb 20 ’24, when Company’s Director bought 250,000 for $9.15, making the entire transaction worth $2,287,500. This insider now owns 320,150 shares in total.
Iovance Biotherapeutics Inc (IOVA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 30.65% per share during the next fiscal year.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Trading Performance Indicators
Check out the current performance indicators for Iovance Biotherapeutics Inc (IOVA). In the past quarter, the stock posted a quick ratio of 2.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2654.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.89, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -0.76 in one year’s time.
Technical Analysis of Iovance Biotherapeutics Inc (IOVA)
The latest stats from [Iovance Biotherapeutics Inc, IOVA] show that its last 5-days average volume of 4.78 million was inferior to 8.76 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 12.11%. Additionally, its Average True Range was 0.83.
During the past 100 days, Iovance Biotherapeutics Inc’s (IOVA) raw stochastic average was set at 45.67%, which indicates a significant increase from 9.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.55% in the past 14 days, which was lower than the 102.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.76, while its 200-day Moving Average is $8.14. Now, the first resistance to watch is $11.66. This is followed by the second major resistance level at $12.02. The third major resistance level sits at $12.34. If the price goes on to break the first support level at $10.98, it is likely to go to the next support level at $10.66. The third support level lies at $10.30 if the price breaches the second support level.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Key Stats
There are currently 279,307K shares outstanding in the company with a market cap of 3.16 billion. Presently, the company’s annual sales total 1,190 K according to its annual income of -444,040 K. Last quarter, the company’s sales amounted to 480 K and its income totaled -116,380 K.
